Gut microbiota modulation by prednisolone in a rat kindling model of pentylenetetrazol (PTZ)-induced seizure

Lima, Amanda Muliterno Domingues Lourenço de; Rosa, Gabriel de Lima; Guzzo, Edson Fernando Müller; Padilha, Rafael Bremm; Silva, Rodrigo da; Silveira, Alexandre Kleber; Morales, Daiana de Lima; Araujo, Milena Conci de; Moreira, José Cláudio Fonseca; Barth, Afonso Luís; Coitinho, Adriana Simon; Sand, Sueli Terezinha Van der

doi:10.1016/j.micpath.2021.105376

Cited by 3 publications

(10 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After excluding the publications not complying with inclusion criteria, 86 records were considered suitable for full-text analysis. After reading these papers and examining their content the two reviewers identified 50 papers [ 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 ,…”

Section: Resultsmentioning

confidence: 99%

“…Seven of the reviewed studies were entirely performed in vitro [ 23 , 25 , 26 , 30 , 31 , 36 , 37 ], twenty-three reported the results of studies performed in vivo only in animal models, eight in rats [ 39 , 42 , 44 , 50 , 51 , 61 , 62 , 70 ] and fifteen in mice [ 43 , 45 , 46 , 47 , 48 , 49 , 52 , 53 , 57 , 58 , 63 , 66 , 67 , 68 , 69 ], whereas one paper included the results of experiments performed in both mice and humans [ 34 ]. Nineteen papers were investigations performed only in humans.…”

Section: Resultsmentioning

confidence: 99%

“…The main findings of the selected studies were summarized in a narrative form in the text of the article and in two tables, the first ( Table 1 ) concerning the papers on the effect of the intestinal microbiota on cIMDs [ 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ], and the second ( Table 2 ) concerning the papers on effect of cIMDs on intestinal microbiota [ 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 ,…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacomicrobiomics of Classical Immunosuppressant Drugs: A Systematic Review

Manes,

Di Renzo,

Dodani

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The clinical response to classical immunosuppressant drugs (cIMDs) is highly variable among individuals. We performed a systematic review of published evidence supporting the hypothesis that gut microorganisms may contribute to this variability by affecting cIMD pharmacokinetics, efficacy or tolerability. The evidence that these drugs affect the composition of intestinal microbiota was also reviewed. The PubMed and Scopus databases were searched using specific keywords without limits of species (human or animal) or time from publication. One thousand and fifty five published papers were retrieved in the initial database search. After screening, 50 papers were selected to be reviewed. Potential effects on cIMD pharmacokinetics, efficacy or tolerability were observed in 17/20 papers evaluating this issue, in particular with tacrolimus, cyclosporine, mycophenolic acid and corticosteroids, whereas evidence was missing for everolimus and sirolimus. Only one of the papers investigating the effect of cIMDs on the gut microbiota reported negative results while all the others showed significant changes in the relative abundance of specific intestinal bacteria. However, no unique pattern of microbiota modification was observed across the different studies. In conclusion, the available evidence supports the hypothesis that intestinal microbiota could contribute to the variability in the response to some cIMDs, whereas data are still missing for others.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacomicrobiomics of Classical Immunosuppressant Drugs: A Systematic Review

Manes,

Di Renzo,

Dodani

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…The results indicated that there was no change in the percentage of α‐diversity. Verrucomicrobia , Saccharibacteria, and Actinobacteria may prevent epilepsy due to their anticonvulsant and anti‐inflammatory characteristics [113].…”

Section: Management Of Epilepsy Based On the Gut–microbiota–brain Axismentioning

confidence: 99%

“…Verrucomicrobia, Saccharibacteria, and Actinobacteria may prevent epilepsy due to their anticonvulsant and anti-inflammatory characteristics [113].…”

Section: Prednisolonementioning

confidence: 99%

The microbiome–gut–brain axis in epilepsy: pharmacotherapeutic target from bench evidence for potential bedside applications

Kundu

Nayak

Rakshit

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

The gut–brain axis augments the bidirectional communication between the gut and brain and modulates gut homeostasis and the central nervous system through the hypothalamic–pituitary–adrenal axis, enteroendocrine system, neuroendocrine system, inflammatory and immune pathways. Preclinical and clinical reports showed that gut dysbiosis might play a major regulatory role in neurological diseases such as epilepsy, Parkinson's, multiple sclerosis, and Alzheimer's disease. Epilepsy is a chronic neurological disease that causes recurrent and unprovoked seizures, and numerous risk factors are implicated in developing epilepsy. Advanced consideration of the gut–microbiota–brain axis can reduce ambiguity about epilepsy pathology, antiepileptic drugs, and effective therapeutic targets. Gut microbiota sequencing analysis reported that the level of Proteobacteria, Verrucomicrobia, Fusobacteria, and Firmicutes was increased and the level of Actinobacteria and Bacteroidetes was decreased in epilepsy patients. Clinical and preclinical studies also indicated that probiotics, ketogenic diet, faecal microbiota transplantation, and antibiotics can improve gut dysbiosis and alleviate seizure by enhancing the abundance of healthy biota. This study aims to give an overview of the connection between gut microbiota, and epilepsy, how gut microbiome changes may cause epilepsy, and whether gut microbiome restoration could be used as a treatment for epilepsy.

show abstract

The interplay between microbiota and brain-gut axis in epilepsy treatment

Zhu,

Wang,

2024

Front. Pharmacol.

View full text Add to dashboard Cite

The brain-gut axis plays a vital role in connecting the cognitive and emotional centers of the brain with the intricate workings of the intestines. An imbalance in the microbiota-mediated brain-gut axis extends far beyond conditions like Irritable Bowel Syndrome (IBS) and obesity, playing a critical role in the development and progression of various neurological disorders, including epilepsy, depression, Alzheimer’s disease (AD), and Parkinson’s disease (PD). Epilepsy, a brain disorder characterized by unprovoked seizures, affects approximately 50 million people worldwide. Accumulating evidence suggests that rebuilding the gut microbiota through interventions such as fecal microbiota transplantation, probiotics, and ketogenic diets (KD) can benefit drug-resistant epilepsy. The disturbances in the gut microbiota could contribute to the toxic side effects of antiepileptic drugs and the development of drug resistance in epilepsy patients. These findings imply the potential impact of the gut microbiota on epilepsy and suggest that interventions targeting the microbiota, such as the KD, hold promise for managing and treating epilepsy. However, the full extent of the importance of microbiota in epilepsy treatment is not yet fully understood, and many aspects of this field remain unclear. Therefore, this article aims to provide an overview of the clinical and animal evidence supporting the regulatory role of gut microbiota in epilepsy, and of potential pathways within the brain-gut axis that may be influenced by the gut microbiota in epilepsy. Furthermore, we will discuss the recent advancements in epilepsy treatment, including the KD, fecal microbiota transplantation, and antiseizure drugs, all from the perspective of the gut microbiota.

show abstract

Gut microbiota modulation by prednisolone in a rat kindling model of pentylenetetrazol (PTZ)-induced seizure

Cited by 3 publications

References 59 publications

Pharmacomicrobiomics of Classical Immunosuppressant Drugs: A Systematic Review

Pharmacomicrobiomics of Classical Immunosuppressant Drugs: A Systematic Review

The microbiome–gut–brain axis in epilepsy: pharmacotherapeutic target from bench evidence for potential bedside applications

The interplay between microbiota and brain-gut axis in epilepsy treatment

Contact Info

Product

Resources

About